Suspected cases of DILI should be reported to the Food and Drug Administration's (FDA's) adverse drug reaction monitoring program (MedWatch), as well as to the DILIN (Drug-Induced Liver Injury Network), a research organization sponsored by the National Institutes of Health (NIH) to improve the understanding of causes and outcomes of DILI in the United States.